Select country set
language
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-29a-3p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0034H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Whole blood, PBMC, Cultural lysates (HeLa)

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.26 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 5.6%

Inter-assay (Run-to-Run)

n = 5,
CV = 7.4%

Spiking Recovery

94.7%

Dilution Linearity

93.1%

Specificity

Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-29a-3p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology, Others, Pulmonary diseases

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-29a are encoded on human chromosome 7q32.3 known as the miR-29a/b-1 cluster. miR-29a-3p has been reported to function as a tumor suppressor in several cancers including colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer, breast cancer and ovarian cancer. miR-29a was down-regulated in metastatic prostate cancer, lung cancer, breast cancer, myeloid leukemias, oral squamous carcinoma and glioblastoma.

The expression of miR-29a and three other miRNAs in serum of patients with advanced stages of CRC was compared to a group of healthy volunteers. Levels of miR-29a were correlated with the clinical stage of CRC.

miR-29a-3p has been shown to act as a regulator of insulin-like growth factor 1 receptor (IGF1R) in (HCC). High expression of miR-29a-3p in HCC tissues provided better prognosis. Thus, restoration of miR-29a-3p expression in HCC cells could reduce cell proliferation and suppress cell migration and tumor formation. miR-29a-3p was also found to be significantly down-regulated in HCC tissues compared to adjacent non-tumor tissues. miR-29a-3p participates in the HCC progression (suppresses cell proliferation) by regulation of NF-κB pathway via targeting PTEN.

Another study showed that inhibition of miR-29a-3p decreased activation of Akt and p38, Inhibition of miR-29a-3p increased cardiomyocyte apoptosis. The level of miR-29a-3p was measured in plasma of acute myocardial infarction (AMI) patients. The circulating miR-29a-3p was significantly decreased in AMI patients compared to healthy controls. ROC curve analysis demonstrated that plasma miR-29a-3p has a considerable diagnostic efficiency, which is comparable to cTnI and CK-MB.

miR-29a was observed in kinds of non-malignant diseases, like Alzheimer’s disease, atherosclerosis, atrial fibrillation, diabetes, active pulmonary tuberculosis, hepatic fibrosis, cholestatic pediatric liver disease, fatty liver disease and scleroderma.

Up-regulation of several miRNAs was observed in gestational hypertension (GH) and preeclampsia (PE). GH and late PE showed up-regulation of miR-17-5p, miR-20b-5p and miR-29a-3p.

Summary References (24)

References to miR-29a-3p

  • Zheng Z, Cui H, Wang Y, Yao W: Downregulation of RPS15A by miR-29a-3p attenuates cell proliferation in colorectal carcinoma. Biosci Biotechnol Biochem. 2019; 83(11):2057-2064.
  • Wang X et al.: miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma. Oncotarget. 2017; 8(49):86592–86603.
  • Yang S et al.: Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011; 25:717–729.
  • Kwon JJ, Willy JA, Quirin KA, Wek RC, Korc M, Yin XM, Kota J: Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. Oncotarget. 2016; 7:71635–71650.
  • Tréhoux S et al.: Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim. Biophys. Acta. 2015; 1853(10Pt A):2392–2403.
  • Muluhngwi P et al.: The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells. Sci. Rep. 2017; 7:5205.
  • Yu PN et al.: Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int. J. Cancer. 2014;134:542–551.
  • Ahmed F, Shiraishi T, Vessella RL, Kulkarni P: Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. Oncol Rep. 2013; 30(6):2963-8.
  • Barkley LR, Santocanale C: MicroRNA-29a regulates the benzo[a]pyrene dihydrodiol epoxide-induced DNA damage response through Cdc7 kinase in lung cancer cells. Oncogenesis. 2013; 2:e57.
  • Muluhngwi P et al.: Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. Cancer Lett. 2017; 388:230-238.
  • Xu L et al.: Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol Oncol. 2014; 3:17.
  • Lu Let al.: MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed Pharmacother. 2014; 68(1):13-9.
  • Xi Z et al.: Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget. 2017; 8(15):24949-24963.
  • Faltejskova P et al.: Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark. 2012; 12(4):199-204.
  • Ma JH, Bu X, Wang JJ, Xie YX: MicroRNA-29-3p Regulates Hepatocellular Carcinoma Progression Through NF-κB Pathway. Clin Lab. 2019; 65(5).
  • Zhang L et al.: Reduction of miR-29a-3p induced cardiac ischemia reperfusion injury in mice via targeting Bax. Exp Ther Med. 2019; 18(3):1729-1737.
  • Müller M et al.: MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid. Mol Neurobiol. 2016; 53(5):2894-2899.
  • Huang YQ, Cai AP, Chen JY, Huang C, Li J, Feng YQ: The Relationship of Plasma miR-29a and Oxidized Low Density Lipoprotein with Atherosclerosis. Cell Physiol Biochem. 2016; 40(6):1521-1528.
  • Zhao Y, Yuan Y, Qiu C: Underexpression of CACNA1C Caused by Overexpression of microRNA-29a Underlies the Pathogenesis of Atrial Fibrillation. Med Sci Monit. 2016; 22:2175-81.
  • Hsu YC et al.: Protective effects of miR-29a on diabetic glomerular dysfunction by modulation of DKK1/Wnt/β-catenin signaling. Sci Rep. 2016; 6:30575.
  • Afum-Adjei Awuah A et al.: Dynamics of T-cell IFN-γ and miR-29a expression during active pulmonary tuberculosis. Int Immunol. 2014; 26(10):579-82.
  • Ndzi EN et al.: MicroRNA hsa-miR-29a-3p is a plasma biomarker for the differential diagnosis and monitoring of tuberculosis. Tuberculosis. 2019; 114:69-76.
  • Yang YL, Wang FS, Li SC, Tiao MM, Huang YH: MicroRNA-29a Alleviates Bile Duct Ligation Exacerbation of Hepatic Fibrosis in Mice through Epigenetic Control of Methyltransferases. Int J Mol Sci. 2017; 18(1):pii: E192.
  • Goldschmidt I, Thum T, Baumann U: Circulating miR-21 and miR-29a as Markers of Disease Severity and Etiology in Cholestatic Pediatric Liver Disea
Related Products Docs